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1411of any single trial did not alter the pooled effect
result. Meta-regression coefﬁcients were not signi-
ﬁcant for hypertension (p ¼ 0.8) or aortic diameter
(p ¼ 0.8).
Most reports of post-AVR aortic dissection include
a limited number of patients and do not differentiate
between BAV phenotypes (1). One systematic review
with 14% of BAV patients found that aortic insufﬁ-
ciency and fragility/thinning of the aortic wall were
predictive of post-AVR dissection (4).
Study limitations include the restricted focus on
BAV function only (i.e., excluding other potentially
important features) and the relevant rate of missing
data (i.e., regarding BAV morphotype and aortic
diameters).
Our meta-analysis revealed a 10-fold higher risk of
aortic dissection in patients who undergo AVR for
BAV insufﬁciency compared with BAV stenosis.
Moreover, the smaller aortic diameters in patients
with BAV insufﬁciency indicate an increased risk of
dissection at smaller diameters in this BAV cohort. In
contrast, BAV stenosis–associated aortopathy seems
to follow a more benign course post-AVR. Such in-
formation may be helpful when deciding on man-
agement of the aorta in BAV patients undergoing AVR
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II287–94.Protamine and
Bleeding Avoidance
StrategiesI read with great interest Dr. Singh’s state-of-the-art
review entitled “Bleeding Avoidance Strategies
During Percutaneous Coronary Interventions” (1).
As he points out, the HEAT-PPCI (Unfractionated
Heparin Versus Bivalirudin in Primary Percutaneous
Coronary Intervention) trial (2) has renewed interest
in heparin monotherapy with pre-loading of dual
antiplatelet therapy during percutaneous coronary
interventions (PCIs). Protamine reversal of heparin
anticoagulation can also be considered as a bleeding
management and/or bleeding avoidance strategy.
Nonetheless, protamine may be underutilized be-
cause of concerns regarding possible heparin re-
bound, cardiac and peripheral thrombotic effects,
and the potential for allergic or anaphylactic re-
actions. Protamine-related adverse events occur in
w2.6% of treated patients but may be as high as 11%
with a less restrictive deﬁnition (3). Briguori et al.
(4) previously concluded that patients who received
protamine to reverse heparin-associated bleeding
complications after coronary stent implantation did
not sustain higher rates of stent thrombosis com-
pared with similar nonprotamine-treated patients.
Protamine is generally well tolerated when routinely
used at the conclusion of cardiopulmonary bypass
procedures in patients with cardiovascular clinical
characteristics similar to patients undergoing PCI.
Meta-analysis of routine utilization of protamine
for the reversal of heparin anticoagulation post-PCI
has shown favorable results in properly selected
patients (5).
Interventionalists may consider protamine reversal
of heparin anticoagulation as a reasonable strategy
for the treatment of signiﬁcant post-procedural
bleeding events. Further clinical studies are appro-
priate to deﬁne the optimal role of protamine
post-femoral access PCI, to reverse heparin anti-
coagulation, and to potentially avoid PCI-associated
bleeding events in patients who have also under-
gone appropriate pre-loading with dual antiplatelet
therapy.
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Bleeding Avoidance StrategiesI greatly appreciate the interest of Dr. Woronow in
my recent study published in the Journal (1). Prot-
amine binds with heparin or low-molecular-weight
heparin to form a stable ion pair with no anticoagu-
lant activity. This compound is routinely used during
cardiopulmonary bypass surgery and is also admin-
istered to reverse the effect of heparin in patients in
stable condition after invasive cardiac catheterization
(e.g., post-transplant evaluation, fractional ﬂow
reserve estimation not requiring percutaneous coro-
nary interventions [PCIs]). Protamine, as mentioned
by the author, is not only important to reverse anti-
coagulation in case of major bleeding after PCI, but it
is also crucial in the uncommon event of cardiac or
coronary perforation during procedures that require
large doses of heparin (2).
There are several reasons that protamine cannot be
routinely used to avoid bleeding after PCI. First, the
allergic reactions to protamine are not uncommon
and can lead to serious anaphylaxis. Second, even
though protamine has been shown to be safe in small
series, case-control, and randomized studies, its
usefulness has not been proven in large contempo-
rary randomized trials (3). Third, its safety has been
tempered with case reports of ischemic complications
in patients treated with protamine (4). Fourth, the
use of the radial artery for access has diminished theutility of protamine reversal in favor of radial artery
patency requiring anticoagulation with heparin.
The role of protamine should be explored further,
and larger, randomized trials need to be planned. In
the meantime, patient selection for use of protamine
is important. Patients with seafood allergies or pre-
vious use of protamine should not be given this drug.
However, patients at very high risk of bleeding (e.g.,
elderly women presenting with acute coronary syn-
drome and who had femoral access for PCI) would be
ideal candidates for protamine administration for
heparin reversal, especially if there are bleeding
events (i.e., hematoma, retroperitoneal bleed).
Rebound thrombogenicity and allergic reactions
to protamine are valid concerns that need to be
addressed. Protamine remains a useful tool in the
armamentarium of interventional cardiologists, and
its judicious use is recommended.*Mandeep Singh, MD, MPH
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Trial Data Into a Hybrid
AmericanCollegeof Cardiology/
American Heart Association
Algorithm for the Allocation
of Statin Therapy in
Primary Prevention
Ridker et al. (1) draw attention to the importance of
statins as primary prevention agents; they endorse
